For acute deep vein thrombosis, which drug is least suitable as treatment?

For acute deep vein thrombosis, which drug is least suitable as treatment?

• A. Clopidogrel
• B. Enoxaparin
• C. Rivaroxaban
• D. Apixaban

Answer: (A)

In acute deep vein thrombosis, the goal is to prevent clot growth and new clots by interrupting the coagulation cascade with anticoagulant therapy. Antiplatelet drugs, like clopidogrel, act mainly on platelets and are more effective for arterial clots where platelets drive thrombosis. Venous clots are driven by the coagulation system and fibrin formation, so antiplatelet therapy alone does not adequately prevent propagation or recurrence of a DVT. Enoxaparin (a low-molecular-weight heparin) enhances antithrombin III to inhibit factors Xa and IIa, making it a standard initial anticoagulant for acute DVT. Rivaroxaban and apixaban are direct oral anticoagulants that directly inhibit factor Xa, also appropriate for treating DVT and often preferred for their convenience and stable dosing. Thus, the antiplatelet drug is the least suitable option for treating acute DVT, because it does not address the coagulation pathway responsible for venous thrombosis.

In acute deep vein thrombosis, the goal is to prevent clot growth and new clots by interrupting the coagulation cascade with anticoagulant therapy. Antiplatelet drugs, like clopidogrel, act mainly on platelets and are more effective for arterial clots where platelets drive thrombosis. Venous clots are driven by the coagulation system and fibrin formation, so antiplatelet therapy alone does not adequately prevent propagation or recurrence of a DVT.

Enoxaparin (a low-molecular-weight heparin) enhances antithrombin III to inhibit factors Xa and IIa, making it a standard initial anticoagulant for acute DVT. Rivaroxaban and apixaban are direct oral anticoagulants that directly inhibit factor Xa, also appropriate for treating DVT and often preferred for their convenience and stable dosing.

Thus, the antiplatelet drug is the least suitable option for treating acute DVT, because it does not address the coagulation pathway responsible for venous thrombosis.